This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – June 6, 2012– Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Roche Holdings Ltd. (RHHBY), Amgen Inc. (AMGN - Analyst Report), Merck KGaA , Eli Lilly & Co. (LLY - Analyst Report) and Bristol-Myers Squibb Company (BMY - Analyst Report)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Positive Data on Roche’s Avastatin
Roche Holdings Ltd. (RHHBY) recently announced positive results on Avastin plus chemotherapy from a phase III study, ML18147 that was conducted with metastatic colorectal cancer (mCRC) patients. On continuing with the treatment, the study showed that mCRC patients lived longer.
Roche said that the study met its primary endpoint and showed an increase in overall survival (OS). As per the study, mortality risk for people continuing with Avastin plus second-line chemotherapy was lower by 19% compared to those who received only chemotherapy (OS of 11.2 months compared to 9.8 months).
Moreover, patients continuing with Avastin plus second-line chemotherapy experienced a significant improvement in progression-free survival (PFS). Cancer progressing risk was reduced by 32% (5.7 months compared to 4.1 months).
Colorectal cancer, considered one of the most common cancers in the world, has over 1.2 million new cases diagnosed each year. This form of cancer is one of the biggest cancer killers in the world with over 600,000 deaths reported every year.
Currently, Amgen Inc.’s (AMGN - Analyst Report) Vectibix and Merck KGaA /Eli Lilly & Co. (LLY - Analyst Report)/Bristol-Myers Squibb Company’s (BMY - Analyst Report) Erbitux are available for mCRC.
Roche also presented results from another phase III study, Aurelia. This study evaluated Avastin plus standard chemotherapy (weekly paclitaxel, topotecan or pegylated liposomal doxorubicin) in ovarian cancer patients whose disease had progressed because of resistance to platinum-containing chemotherapy.
Roche reported that the study demonstrated a 52% reduction in the risk of progression in patients in the Avastin plus chemotherapy arm compared to patients who received only chemotherapy (OS of 6.7 months compared to 3.4 months). The study met its primary endpoint of an improvement in PFS.
Ovarian cancer is one of the most commonly diagnosed cancers in women and one of the leading causes of cancer death in women around the world. According to the press release issued by Roche, around 230,000 women will be diagnosed with this cancer and approximately 140,000 will die from the disease.
Roche currently retains a Zacks #3 Rank (short-term Hold rating).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339